Business
Crescita Reports First Quarter 2025 Results
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or th...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"Crescita Reports First Quarter 2025 Results\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwdoublebottom { border-bottom: double black 2.25pt }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadb4 { padding-bottom: 5px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl20 { padding-left: 100px }\n.bwpadr0 { padding-right: 0px }\n.bwrowaltcolor0 { background-color: #cceeff }\n.bwrowaltcolor1 { background-color: #d3d3d3 }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth1 { width: 1% }\n.bwwidth10 { width: 10% }\n.bwwidth100 { width: 100% }\n.bwwidth11 { width: 11% }\n.bwwidth64 { width: 64% }\n \n\n\n\n Crescita Therapeutics Inc. (\n \n TSX: CTX\n \n and\n \n OTC US: CRRTF\n \n ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2025 (“Q1-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.\n \n\n\n Financial Highlights\n \n\n\n\n Q1-2025 vs. Q1-2024\n \n\n\n\n Revenue was $3,537, compared to $4,996, a decrease of $1,459;\n \n\n Gross profit was $1,747, compared to $2,411, a decrease of $664;\n \n\n Operating expenses were $2,809, compared to $3,142, a decrease of $333;\n \n\n Net loss was $(932), compared to $(626), an increase of $306;\n \n\n Adjusted EBITDA\n \n 1\n \n was $(679), compared to $(325), an increased loss of $354;\n \n\n Ending cash of $8,538, compared to $9,273, a decrease of $735 for the quarter.\n \n\n\n “As anticipated, our Q1 results were less than the prior year, mainly due to the timing of order fulfillment in our Manufacturing segment. A large purchase order was fulfilled in Q1-2024 whereas some deli...